Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026)

Vanda Pharmaceuticals has disclosed Gross Profit across 14 years of filings, most recently posting $48.6 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $48.6 million, up 4.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $205.1 million (up 7.97% YoY), and the FY2025 annual result was $203.1 million, up 8.32% from the prior year.
• Gross Profit came in at $48.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $53.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $59.0 million in Q3 2022 to a low of $35.8 million in Q3 2023.
• The 5-year median for Gross Profit is $49.9 million (2025), against an average of $49.8 million.
• Across the five-year window, Gross Profit tumbled 39.4% in 2023 and increased 26.15% in 2024, its largest moves.
• Vanda Pharmaceuticals' Gross Profit stood at $58.2 million in 2022, then slipped by 28.21% to $41.8 million in 2023, then rose by 21.01% to $50.6 million in 2024, then gained by 5.51% to $53.4 million in 2025, then fell by 9.04% to $48.6 million in 2026.
• The last three Gross Profit figures came in at $48.6 million (Q1 2026), $53.4 million (Q4 2025), and $53.3 million (Q3 2025), per Business Quant data.